Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 5, Pages 551–559
http://dx.doi.org/10.1155/2013/563717
Review Article

Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment

1Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
2The Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China

Received 31 May 2013; Revised 3 September 2013; Accepted 4 September 2013

Academic Editor: Francisco Blanco-Vaca

Copyright © 2013 Anping Cai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. M. Gibson, Y. B. Pride, C. P. Hochberg, S. Sloan, M. S. Sabatine, and C. P. Cannon, “Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) substudy,” Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2290–2295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. P. M. Kearney, L. Blackwell, R. Collins et al., “Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis,” The Lancet, vol. 371, no. 9607, pp. 117–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. C. P. Cannon, B. A. Steinberg, S. A. Murphy, J. L. Mega, and E. Braunwald, “Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy,” Journal of the American College of Cardiology, vol. 48, no. 3, pp. 438–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Armitage, L. Bowman, K. Wallendszus et al., “Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12, 064 survivors of myocardial infarction: a double-blind randomised trial,” The Lancet, vol. 376, no. 9753, pp. 1658–1669, 2010. View at Google Scholar
  5. C. Baigent, L. Blackwell, J. Emberson et al., “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials,” The Lancet, vol. 376, no. 9753, pp. 1670–1681, 2010. View at Google Scholar
  6. C. P. Cannon, E. Braunwald, C. H. McCabe et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1495–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. J. C. LaRosa, S. M. Grundy, D. D. Waters et al., “Intensive lipid lowering with atorvastatin in patients with stable coronary disease,” The New England Journal of Medicine, vol. 352, no. 14, pp. 1425–1435, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Chapman, “Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention,” Cardiovascular Drugs and Therapy, vol. 19, no. 2, pp. 135–139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Schachter, “Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid,” Cardiovascular Drugs and Therapy, vol. 19, no. 6, pp. 415–422, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. K. Shah, “Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease,” European Heart Journal, vol. 28, no. 1, pp. 5–12, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Y. Campbell, J. J. Rivera, and R. S. Blumenthal, “Residual risk in statin-treated patients: future therapeutic options,” Current Cardiology Reports, vol. 9, no. 6, pp. 499–505, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos, “Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions,” Clinical Chemistry, vol. 49, no. 11, pp. 1785–1796, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Danesh, R. Collins, and R. Peto, “Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies,” Circulation, vol. 102, no. 10, pp. 1082–1085, 2000. View at Google Scholar · View at Scopus
  14. A. A. Ariyo, C. Thach, and R. Tracy, “Lp(a) lipoprotein, vascular disease, and mortality in the elderly,” The New England Journal of Medicine, vol. 349, no. 22, pp. 2108–2115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Erqou, S. Kaptoge, P. L. Perry et al., “Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality,” Journal of the American Medical Association, vol. 302, no. 4, pp. 412–423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Hoover-Plow and M. Huang, “Lipoprotein(a) metabolism: potential sites for therapeutic targets,” Metabolism, vol. 62, no. 4, pp. 479–491, 2013. View at Google Scholar
  17. P. R. Kamstrup, “Lipoprotein(a) and ischemic heart disease—a causal association? A review,” Atherosclerosis, vol. 211, no. 1, pp. 15–23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. Marcovina, J. J. Albers, D. R. Jacobs Jr. et al., “Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans: the CARDIA study,” Arteriosclerosis and Thrombosis, vol. 13, no. 7, pp. 1037–1045, 1993. View at Google Scholar · View at Scopus
  19. J. Rubin, H. J. Kim, T. A. Pearson, S. Holleran, L. Berglund, and R. Ramakrishnan, “The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians,” Atherosclerosis, vol. 201, no. 1, pp. 138–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Boerwinkle, H. J. Menzel, H. G. Kraft, and G. Utermann, “Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation,” Human Genetics, vol. 82, no. 1, pp. 73–78, 1989. View at Google Scholar · View at Scopus
  21. S. Erqou, A. Thompson, E. Di Angelantonio et al., “Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants,” Journal of the American College of Cardiology, vol. 55, no. 19, pp. 2160–2167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Kardys, R. M. Oemrawsingh, I. P. Kay et al., “Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention,” Clinical Cardiology, vol. 35, no. 8, pp. 482–489, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Momiyama, R. Ohmori, Z. A. Fayad et al., “Associations between serum lipoprotein(a) levels and the severity of coronary and aortic atherosclerosis,” Atherosclerosis, vol. 222, no. 1, pp. 241–244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. D. J. Suk, N. Rifai, and J. E. Buring, “Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events,” Journal of the American College of Cardiology, vol. 52, no. 2, pp. 124–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. H. Davidson, C. M. Ballantyne, T. A. Jacobson et al., “Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists,” Journal of Clinical Lipidology, vol. 5, no. 5, pp. 338–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. B. G. Nordestgaard, M. J. Chapman, K. Ray et al., “Lipoprotein(a) as a cardiovascular risk factor: current status,” European Heart Journal, vol. 31, no. 23, pp. 2844–2853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. I. Chasman, D. Shiffman, R. Y. L. Zee et al., “Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy,” Atherosclerosis, vol. 203, no. 2, pp. 371–376, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Berg, “A new serum type system in man—the Lp system,” Acta Pathologica et Microbiologica Scandinavica, vol. 59, pp. 369–382, 1963. View at Google Scholar · View at Scopus
  29. M. L. Koschinsky, G. P. Cote, B. Gabel, and Y. Y. van der Hoek, “Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100,” The Journal of Biological Chemistry, vol. 268, no. 26, pp. 19819–19825, 1993. View at Google Scholar · View at Scopus
  30. J. W. McLean, J. E. Tomlinson, W.-J. Kuang et al., “cDNA sequence of human apolipoprotein(a) is homologous to plasminogen,” Nature, vol. 330, no. 6144, pp. 132–137, 1987. View at Google Scholar · View at Scopus
  31. L. A. Miles and E. F. Plow, “Lp(a): an interloper into the fibrinolytic system?” Thrombosis and Haemostasis, vol. 63, no. 3, pp. 331–335, 1990. View at Google Scholar · View at Scopus
  32. N. Malgaretti, F. Acquati, P. Magnaghi et al., “Characterization by yeast artificial chromosome cloning of the linked apolipoprotein(a) and plasminogen genes and identification of the apolipoprotein(a) 5′ flanking region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 23, pp. 11584–11588, 1992. View at Google Scholar
  33. Y. Y. van der Hoek, M. E. Wittekoek, U. Beisiegel, J. J. P. Kastelein, and M. L. Koschinsky, “The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms,” Human Molecular Genetics, vol. 2, no. 4, pp. 361–366, 1993. View at Google Scholar · View at Scopus
  34. C. Lackner, J. C. Cohen, and H. H. Hobbs, “Molecular definition of the extreme size polymorphism in apolipoprotein(a),” Human Molecular Genetics, vol. 2, no. 7, pp. 933–940, 1993. View at Google Scholar · View at Scopus
  35. L. Berglund and R. Ramakrishnan, “Lipoprotein(a): an elusive cardiovascular risk factor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 12, pp. 2219–2226, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. B. R. Gabel and M. L. Koschinsky, “Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a),” Biochemistry, vol. 34, no. 48, pp. 15777–15784, 1995. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Utermann, H. J. Menzel, H. G. Kraft, H. C. Duba, H. G. Kemmler, and C. Seitz, “Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma,” The Journal of Clinical Investigation, vol. 80, no. 2, pp. 458–465, 1987. View at Google Scholar · View at Scopus
  38. M. L. Koschinsky, G. P. Cote, B. Gabel, and Y. Y. van der Hoek, “Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100,” The Journal of Biological Chemistry, vol. 268, no. 26, pp. 19819–19825, 1993. View at Google Scholar · View at Scopus
  39. L. Becker, P. M. Cook, T. G. Wright, and M. L. Koschinsky, “Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly,” The Journal of Biological Chemistry, vol. 279, no. 4, pp. 2679–2688, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. S. M. Marcovina, H. H. Hobbs, and J. J. Albers, “Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature,” Clinical Chemistry, vol. 42, no. 3, pp. 436–439, 1996. View at Google Scholar · View at Scopus
  41. D. K. Bonen, A. M. L. Hausman, C. Hadjiagapiou, S. F. Skarosi, and N. O. Davidson, “Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a),” The Journal of Biological Chemistry, vol. 272, no. 9, pp. 5659–5667, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Lobentanz, K. Krasznai, A. Gruber et al., “Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells,” Biochemistry, vol. 37, no. 16, pp. 5417–5425, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. V. N. Trieu and W. J. McConathy, “A two-step model for lipoprotein(a) formation,” The Journal of Biological Chemistry, vol. 270, no. 26, pp. 15471–15474, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. S. P. McCormick, “Lipoprotein(a): biology and clinical importance,” The Clinical Biochemist Reviews, vol. 25, no. 1, pp. 69–80, 2004. View at Google Scholar
  45. C. Brunner, E. Lobentanz, A. Pethö-Schramm et al., “The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells,” The Journal of Biological Chemistry, vol. 271, no. 50, pp. 32403–32410, 1996. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Boffelli, D. A. Zajchowski, Z. Yang, and R. M. Lawn, “Estrogen modulation of apolipoprotein(a) expression: identification of a regulatory element,” The Journal of Biological Chemistry, vol. 274, no. 22, pp. 15569–15574, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. D. P. Wade, J. G. Clarke, G. E. Lindahl et al., “5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1369–1373, 1993. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Boerwinkle, C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H. H. Hobbs, “Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations,” The Journal of Clinical Investigation, vol. 90, no. 1, pp. 52–60, 1992. View at Google Scholar · View at Scopus
  49. J. C. Cohen, G. Chiesa, and H. H. Hobbs, “Sequence polymorphisms in the apolipoprotein(a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels,” The Journal of Clinical Investigation, vol. 91, no. 4, pp. 1630–1636, 1993. View at Google Scholar · View at Scopus
  50. H. H. Hobbs and A. L. White, “Lipoprotein(a): intrigues and insights,” Current Opinion in Lipidology, vol. 10, no. 3, pp. 225–236, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. L. H. Puckey and B. L. Knight, “Sequence and functional changes in a putative enhancer region upstream of the apolipoprotein(a) gene,” Atherosclerosis, vol. 166, no. 1, pp. 119–127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Huby, V. Afzal, C. Doucet et al., “Regulation of the expression of the apolipoprotein(a) gene: evidence for a regulatory role of the 5′ distal apolipoprotein(a) transcription control region enhancer in yeast artificial chromosome transgenic mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 9, pp. 1633–1639, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. S. L. Hofmann, D. L. Eaton, M. S. Brown, W. J. McConathy, J. L. Goldstein, and R. E. Hammer, “Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice,” The Journal of Clinical Investigation, vol. 85, no. 5, pp. 1542–1547, 1990. View at Google Scholar · View at Scopus
  54. H. G. Kraft, A. Lingenhel, F. J. Raal, M. Hohenegger, and G. Utermann, “Lipoprotein(a) in homozygous familial hypercholesterolemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 2, pp. 522–528, 2000. View at Google Scholar · View at Scopus
  55. B. L. Knight, Y. F. N. Perombelon, A. K. Soutar, D. P. Wade, and M. Seed, “Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects,” Atherosclerosis, vol. 87, no. 2-3, pp. 227–237, 1991. View at Google Scholar · View at Scopus
  56. D. J. Rader, W. A. Mann, W. Cain et al., “The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans,” The Journal of Clinical Investigation, vol. 95, no. 3, pp. 1403–1408, 1995. View at Google Scholar · View at Scopus
  57. K. M. Argraves, K. F. Kozarsky, J. T. Fallon, P. C. Harpel, and D. K. Strickland, “The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor,” The Journal of Clinical Investigation, vol. 100, no. 9, pp. 2170–2181, 1997. View at Google Scholar · View at Scopus
  58. C. Edelstein, J. A. Italia, and A. M. Scanu, “Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments,” The Journal of Biological Chemistry, vol. 272, no. 17, pp. 11079–11087, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Kronenberg, E. Trenkwalder, A. Lingenhel et al., “Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation,” Journal of Lipid Research, vol. 38, no. 9, pp. 1755–1763, 1997. View at Google Scholar · View at Scopus
  60. L. A. Sechi, L. Zingaro, S. De Carli et al., “Increased serum lipoprotein(a) levels in patients with early renal failure,” Annals of Internal Medicine, vol. 129, no. 6, pp. 457–461, 1998. View at Google Scholar · View at Scopus
  61. M. E. Frischmann, F. Kronenberg, E. Trenkwalder et al., “In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients,” Kidney International, vol. 71, no. 10, pp. 1036–1043, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. K. M. Kostner, S. Banyai, M. Banyai et al., “Urinary apolipoprotein(a) excretion in patients with proteinuria,” Annals of Medicine, vol. 30, no. 5, pp. 497–502, 1998. View at Google Scholar · View at Scopus
  63. K. Oida, H. Takai, H. Maeda et al., “Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure,” Clinical Chemistry, vol. 38, no. 11, pp. 2244–2248, 1992. View at Google Scholar · View at Scopus
  64. M. B. Boffa, S. M. Marcovina, and M. L. Koschinsky, “Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models,” Clinical Biochemistry, vol. 37, no. 5, pp. 333–343, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. M. L. Koschinsky and S. M. Marcovina, “Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity,” Current Opinion in Lipidology, vol. 15, no. 2, pp. 167–174, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Kronenberg, M. F. Kronenberg, S. Kiechl et al., “Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the bruneck study,” Circulation, vol. 100, no. 11, pp. 1154–1160, 1999. View at Google Scholar · View at Scopus
  67. J. Danesh and S. Erqou, “Risk factors: lipoprotein(a) and coronary disease-moving closer to causality,” Nature Reviews, vol. 6, no. 9, pp. 565–567, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Tsimikas and J. L. Witztum, “The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity,” Current Opinion in Lipidology, vol. 19, no. 4, pp. 369–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Tsimikas, J. L. Witztum, E. R. Miller et al., “High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial,” Circulation, vol. 110, no. 11, pp. 1406–1412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Tsimikas, S. Kiechl, J. Willeit et al., “Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study,” Journal of the American College of Cardiology, vol. 47, no. 11, pp. 2219–2228, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Tsimikas, E. S. Brilakis, E. R. Miller et al., “Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease,” The New England Journal of Medicine, vol. 353, no. 1, pp. 46–57, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Tsimikas, C. Bergmark, R. W. Beyer et al., “Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes,” Journal of the American College of Cardiology, vol. 41, no. 3, pp. 360–370, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Tsimikas, H. K. Lau, K. Han et al., “Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein,” Circulation, vol. 109, no. 25, pp. 3164–3170, 2004. View at Google Scholar · View at Scopus
  74. S. Karabina and E. Ninio, “Plasma PAF-acetylhydrolase: an unfulfilled promise?” Biochimica et Biophysica Acta, vol. 1761, no. 11, pp. 1351–1358, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Morgan, E. M. Boyle Jr., W. Yun et al., “Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury,” Circulation, vol. 100, supplement 19, pp. II365–II368, 1999. View at Google Scholar · View at Scopus
  76. R. Quarck, B. De Geest, D. Stengel et al., “Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 103, no. 20, pp. 2495–2500, 2001. View at Google Scholar · View at Scopus
  77. G. Theilmeier, B. De Geest, P. P. van Veldhoven et al., “HDL-associated PAF-AH reduces endothelial adhesiveness in apoE(-/-) mice,” The FASEB Journal, vol. 14, no. 13, pp. 2032–2039, 2000. View at Google Scholar · View at Scopus
  78. H. Noto, M. Hara, K. Karasawa et al., “Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 829–835, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. M. J. Caslake, C. J. Packard, K. E. Suckling, S. D. Holmes, P. Chamberlain, and C. H. Macphee, “Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease,” Atherosclerosis, vol. 150, no. 2, pp. 413–419, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. R. S. Rosenson, “Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes,” Current Opinion in Lipidology, vol. 21, no. 6, pp. 473–480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. D. Mannheim, J. Herrmann, D. Versari et al., “Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques,” Stroke, vol. 39, no. 5, pp. 1448–1455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Blankenberg, D. Stengel, H. J. Rupprecht et al., “Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis,” Journal of Lipid Research, vol. 44, no. 7, pp. 1381–1386, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. T. R. Pedersen, “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S),” The Lancet, vol. 344, no. 8934, pp. 1383–1389, 1994. View at Google Scholar · View at Scopus
  84. A. Cai, D. Zheng, R. Qiu, W. Mai, and Y. Zhou, “Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment,” Disease Markers, vol. 34, no. 5, pp. 323–331, 2013. View at Google Scholar
  85. V. Nambi and C. M. Ballantyne, “Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events,” Current Atherosclerosis Reports, vol. 8, no. 5, pp. 374–381, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. L. D. Tsironis, C. S. Katsouras, E. S. Lourida et al., “Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease,” Atherosclerosis, vol. 177, no. 1, pp. 193–201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Tsimikas, L. D. Tsironis, and A. D. Tselepis, “New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 10, pp. 2094–2099, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. L. Hervio, A. Girard-Globa, V. Durlach, and E. Anglés-Cano, “The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin,” European Journal of Clinical Investigation, vol. 26, no. 5, pp. 411–417, 1996. View at Google Scholar · View at Scopus
  89. S. Erqou, A. Thompson, E. Di Angelantonio et al., “Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants,” Journal of the American College of Cardiology, vol. 55, no. 19, pp. 2160–2167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. J. S. Danik, N. Rifai, J. E. Buring, and P. M. Ridker, “Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women,” Journal of the American Medical Association, vol. 296, no. 11, pp. 1363–1370, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Rifai, J. Ma, F. M. Sacks et al., “Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the physicians' health study,” Clinical Chemistry, vol. 50, no. 8, pp. 1364–1371, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. P. R. Kamstrup, A. Tybjærg-Hansen, R. Steffensen, and B. G. Nordestgaard, “Genetically elevated lipoprotein(a) and increased risk of myocardial infarction,” Journal of the American Medical Association, vol. 301, no. 22, pp. 2331–2339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. J.-P. Chretien, J. Coresh, Y. Berthier-Schaad et al., “Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans,” Journal of Medical Genetics, vol. 43, no. 12, pp. 917–923, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. M. B. Lanktree, S. S. Anand, S. Yusuf, and R. A. Hegele, “Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians,” Circulation, vol. 3, no. 1, pp. 39–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. R. Clarke, J. F. Peden, J. C. Hopewell et al., “Genetic variants associated with Lp(a) lipoprotein level and coronary disease,” The New England Journal of Medicine, vol. 361, no. 26, pp. 2518–2528, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Erqou, A. Thompson, E. Di Angelantonio et al., “Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants,” Journal of the American College of Cardiology, vol. 55, no. 19, pp. 2160–2167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. Li, M. M. Luke, D. Shiffman, and J. J. Devlin, “Genetic variants in the apolipoprotein(a) gene and coronary heart disease,” Circulation, vol. 4, no. 5, pp. 565–573, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. M. M. Luke, J. P. Kane, D. M. Liu et al., “A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 9, pp. 2030–2036, 2007. View at Google Scholar
  99. D. Shiffman, E. S. O'Meara, L. A. Bare et al., “Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 1, pp. 173–179, 2008. View at Google Scholar
  100. J. C. Hopewell, R. Clarke, S. Parish et al., “Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the heart protection study,” Circulation, vol. 4, no. 1, pp. 68–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. D. Shiffman, J. Z. Louie, C. M. Rowland, M. J. Malloy, J. P. Kane, and J. J. Devlin, “Single variants can explain the association between coronary heart disease and haplotypes in the apolipoprotein(a) locus,” Atherosclerosis, vol. 212, no. 1, pp. 193–196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. L. A. Carlson, A. Hamsten, and A. Asplund, “Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid,” Journal of Internal Medicine, vol. 226, no. 4, pp. 271–276, 1989. View at Google Scholar · View at Scopus
  103. G. B. Vigna, P. Donegà, R. Zanca et al., “Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial,” Metabolism, vol. 51, no. 11, pp. 1463–1470, 2002. View at Google Scholar · View at Scopus
  104. M. Taskinen, J. Puolakka, T. Pyörälä et al., “Hormone replacement therapy lowers plasma Lp(a) concentrations: comparison of cyclic transdermal and continuous estrogen-progestin regimens,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 10, pp. 1215–1221, 1996. View at Google Scholar · View at Scopus
  105. I. F. Godsland, “Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000,” Fertility and Sterility, vol. 75, no. 5, pp. 898–915, 2001. View at Publisher · View at Google Scholar · View at Scopus
  106. E. Bruckert, J. Labreuche, and P. Amarenco, “Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis,” Atherosclerosis, vol. 210, no. 2, pp. 353–361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. M. G. Shlipak, J. A. Simon, E. Vittinghoff et al., “Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease events after menopause,” Journal of the American Medical Association, vol. 283, no. 14, pp. 1845–1852, 2000. View at Google Scholar · View at Scopus
  108. G. Lippi and G. Targher, “Optimal therapy for reduction of lipoprotein(a),” Journal of Clinical Pharmacy and Therapeutics, vol. 37, no. 1, pp. 1–3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Ramharack, D. Barkalow, and M. A. Spahr, “Dominant negative effect of TGF-β1 and TNF-α on basal and IL-6- induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 6, pp. 984–990, 1998. View at Google Scholar · View at Scopus
  110. O. Schultz, F. Oberhauser, J. Saech et al., “Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases,” PLoS ONE, vol. 5, no. 12, Article ID e14328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. J. M. McKenney, M. J. Koren, D. J. Kereiakes, C. Hanotin, A. Ferrand, and E. A. Stein, “Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy,” Journal of the American College of Cardiology, vol. 59, no. 25, pp. 2344–2353, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. G. Lippi, M. Franchini, and G. Targher, “Platelets and lipoprotein(a) in retinal vein occlusion: mutual targets for aspirin therapy,” Thrombosis and Haemostasis, vol. 97, no. 6, pp. 1059–1060, 2007. View at Publisher · View at Google Scholar · View at Scopus